AI-based radiomic features predict outcomes and the added benefit of chemoimmunotherapy over chemotherapy in extensive stage small cell lung cancer: A Multi-institutional study.
Authors
Affiliations (6)
Affiliations (6)
- Emory University and Georgia Institute of Technology, Atlanta, Georgia 30322.
- Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA.
- Department of Radiation Oncology, Winship Cancer Institute and Emory University.
- Department of medicine and thoracic Oncology, Roswell park Cancer Center, Buffalo, NY.
- Department of Radiation Oncology, City of Hope Cancer Center, Atlanta, GA.
- Emory University and Georgia Institute of Technology, Atlanta, Georgia 30322; Atlanta Veterans Affairs Medical Center, Atlanta, GA. Electronic address: [email protected].
Abstract
Small cell lung cancer (SCLC) is aggressive with poor survival outcomes, and most patients develop resistance to chemotherapy. No predictive biomarkers currently guide therapy. This study evaluates radiomic features to predict PFS and OS in limited-stage SCLC (LS-SCLC) and assesses PFS, OS, and the added benefit of chemoimmunotherapy (CHIO) in extensive-stage SCLC (ES-SCLC). A total of 660 SCLC patients (470 ES-SCLC, 190 LS-SCLC) from three sites were analyzed. LS-SCLC patients received chemotherapy and radiation, while ES-SCLC patients received either chemotherapy alone or chemoimmunotherapy. Radiomic and quantitative vasculature tortuosity features were extracted from CT scans. A LASSO-Cox regression model was used to construct the ES- Risk-Score (ESRS) and LS- Risk-Score (LSRS). ESRS was associated with PFS in training (HR = 1.54, adj. P = .0013) and validation sets (HR = 1.32, adj. P = .0001; HR = 2.4, adj. P = .0073) and with OS in training (HR = 1.37, adj. P = .0054) and validation sets (HR = 1.35, adj. P < .0006; HR = 1.6, adj. P < .0085) in ES-SCLC patients treated with chemotherapy. High-risk patients had improved PFS (HR = 0.68, adj. P < .001) and OS (HR = 0.78, adj. P = .026) with chemoimmunotherapy. LSRS was associated with PFS in training and validation sets (HR = 1.9, adj. P = .007; HR = 1.4, adj. P = .0098; HR = 2.1, adj. P = .028) in LS-SCLC patients receiving chemoradiation. Radiomics is prognostic for PFS and OS and predicts chemoimmunotherapy benefit in high-risk ES-SCLC patients.